Brazil Channel De-stocking Uncertainty
Q4 sales impacted by channel de-stocking due to expectation of low price increases for 2025-26. Full-year FY26 impact unclear as management could not quantify impact on EBITDA margins.
TORNTPHARM / Q4-FY25 / risks
Keep the risk register visible.
Torrent Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Semaglutide Timing and Approval Uncertainty
Management explicitly refused to predict timing for Brazil launch, stating even filers in advanced markets like U.S. face approval delays. Market could see 5-10 filers but approvals not straightforward.
Insulin CMO Sales Shortfall vs Guidance
Management had guided INR 120 crore quarterly run-rate recovery in Q4 but actual was only INR 75 crore. Catch-up expected in Q1-Q2 FY26 but quantum uncertain; suggests either lost contracts or timing mismatch.
Entresto Launch Opportunity Diminishing
Despite pediatric exclusivity ending July 15, management indicated the generic opportunity is smaller than anticipated months ago due to delays. Multiple players expected simultaneously, pressuring market share potential.